Relationship Between Formalin Reagent and Success Rate of Targeted Sequencing Analysis Using Formalin Fixed Paraffin Embedded Tissues
Overview
Affiliations
Background: Tumor genetic alterations are determined to aid in selecting therapy and predicting prognosis. In routine clinical practice, targeted sequencing analysis is performed using formalin-fixed paraffin embedded (FFPE) tissues. However, successful genetic analysis remains challenging because FFPE DNA is fragmented during the sample preparation process.
Methods: Real-time PCR was performed to assess DNA quality and quantities. Targeted sequencing was performed using FFPE tissues fixed with different types of formalin.
Results: DNA was less fragmented from samples fixed in low formalin concentration (10% vs. 20%) and neutral buffered conditions (neutral buffered vs. non-neutral). DNA fragmentation increased over the fixation time. In a preliminary test study, we compared fixation using 10% neutral buffered formalin (n = 180) and 20% formalin (n = 26). The success rate of targeted analysis was higher using 10% neutral formalin (98.3%; 177/180) compared with 20% formalin (34.6%; 9/26). In a validation study with additional formalin-fixed paraffin embedded tissues fixed with 10% neutral buffered formalin (n = 860), we reproduced these results and achieved a high success rate for targeted sequencing analysis (98.4%; 846/860).
Conclusion: Our data show that 10% neutral buffered formalin is recommended for fixation of formalin-fixed paraffin embedded samples to achieve high success rate of targeted sequencing analysis.
Dar G, Nazir R, Wani S, Farooq S, Aziz T, Albekairi T Open Life Sci. 2025; 20(1):20221006.
PMID: 39926474 PMC: 11806203. DOI: 10.1515/biol-2022-1006.
Hirotsu Y, Nakagomi T, Nagakubo Y, Goto T, Omata M Sci Rep. 2024; 14(1):1594.
PMID: 38238401 PMC: 10796947. DOI: 10.1038/s41598-024-52006-6.
A critical spotlight on the paradigms of FFPE-DNA sequencing.
Steiert T, Parra G, Gut M, Arnold N, Trotta J, Tonda R Nucleic Acids Res. 2023; 51(14):7143-7162.
PMID: 37351572 PMC: 10415133. DOI: 10.1093/nar/gkad519.
Nagakubo Y, Hirotsu Y, Amemiya K, Mochizuki H, Tsutsui T, Kakizaki Y Mol Diagn Ther. 2023; 27(4):513-523.
PMID: 37198423 DOI: 10.1007/s40291-023-00653-2.
Sakamoto I, Hirotsu Y, Amemiya K, Nozaki T, Mochizuki H, Omata M J Gynecol Oncol. 2022; 34(1):e6.
PMID: 36245225 PMC: 9807354. DOI: 10.3802/jgo.2023.34.e6.